

## Legendary In Pharmacy



### Dr. C. J. Shishoo

Hon. Director

B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, S. G. Highway, Thaltej, Ahmedabad-380 054

**Phone :** +91 79 27439375 / 27416409 (Off);

**Mobile:** 9825577542

**Email:** [perd@perdcentre.com](mailto:perd@perdcentre.com) /  
[cjshishoo@perdcentre.com](mailto:cjshishoo@perdcentre.com) /  
[chamanshishoo@yahoo.com](mailto:chamanshishoo@yahoo.com)

Associated in various capacities with L. M. College of Pharmacy, Ahmedabad, for more than 33 years, Dr. C. J. Shishoo retired as Principal, Head and Professor, Dept. of Pharmaceutical Chemistry, in 1997. He got his Master's degree in Pharmaceutical Chemistry in 1963 from the University of Iowa (USA) and got his Ph.D. in Pharmaceutical Chemistry from Gujarat University in 1976. He is presently working as Hon. Director of B.V. Patel PERD, Ahmedabad. As Chairman of Suraksha Independent Ethics Committee for the last seven years, he has been associated with several Phase I, II and III clinical trials.

Essentially, due to his untiring zeal and infectious enthusiasms, Dr. Shishoo could establish a very strong Medicinal Chemistry research programme in the college,

one of the best in the country. He has been working for more than 30 years in the field of Pyrimidine and condensed pyrimidine chemistry and has developed simple and facile methods to synthesize pyrimidines and condensed pyrimidines. Essentially, using this method, his research group has prepared more than 3000 fused pyrimidines as potential medicinal compounds. His work on pyrimidines has been recognized as an important contribution to the chemistry. A novel method of synthesizing pyrimidines and condensed pyrimidines was the subject of an extensive Review in Heterocycles. LM-1554, a potent and safe antihyperlipidemic compound has been the subject of intense study as potential drug in several R and D laboratories.

Recently, his work on the interaction of Rifampicin and Isoniazid has revealed that the presence of isoniazid enhances degradation of rifampicin in the acidic environment of stomach which is reflected in impaired bioavailability of rifampicin from rifampicin-isoniazid fixed dose combination (FDC) formulations. A novel NDDS formulation of these two antitubercular drugs is undergoing clinical trial at AIIMS, New Delhi.

Dr. Shishoo has published more than 100 original scientific papers in reputed national and international journals. He has also co-authored several reviews and holds two patents.

Dr. Shishoo is a member of American Chemical Society, member – Medicinal Chemistry Division. He is on the Editorial Board of Indian Journal of Pharmaceutical Sciences and also International Journal of Pharmaceutical Excipients. After retirement from the college, he was associated with consumer movement in India as a Trustee and as Advisor to the Compound Testing Laboratory of Consumer Education and Research Centre, Ahmedabad, for 15 years. Widely travelled, he has visited USA, Europe and Asia.